MA
Therapeutic Areas
Precision BioSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PBGENE-HBV | Chronic Hepatitis B Virus (HBV) Infection | Phase 1/2 |
| PBGENE-DMD | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 |
| Azer-cel (PBCAR0191) | Multiple Sclerosis | Phase 1/2 |
Leadership Team at Precision BioSciences
JA
John A. Kelly
Chief Financial Officer
DJ
Derek J. Jantz, Ph.D.
Chief Scientific Officer & Co-Founder
AG
Alexandra Glucksmann, Ph.D.
Chief Operating Officer
BD
Brendan D. Miller
General Counsel
BJ
B. Jefferson (Jeff) Smith, Ph.D.
SVP, Corporate Development & Strategy
MC
Matthew C. Kane
President & Chief Business Officer